| Name | Market Cap | Current Price | P/E Ratio | Revenue Growth 1Y | Net Margin | ROE | FCF Yield | Debt/Equity |
|---|---|---|---|---|---|---|---|---|
| KRYSKrystal Biotech, Inc. | 8.18B | 282.01 | 94.00 | 473.02% | 53.3% | 17.48% | 1.46% | 0.01 |
| BMRNBioMarin Pharmaceutical Inc. | 10.58B | 55.07 | 24.92 | 17.97% | 16.82% | 8.59% | 4.49% | 0.11 |
| SRPTSarepta Therapeutics, Inc. | 2.23B | 21.31 | 9.11 | 52.97% | -11.25% | -20.57% | 0.88 | |
| RAREUltragenyx Pharmaceutical Inc. | 2.27B | 23.50 | -3.74 | 29.01% | -91.95% | -35.88% | 0.15 | |
| DYNDyne Therapeutics, Inc. | 2.7B | 16.42 | -4.87 | -61.26% | 0.04 | |||
| TVTXTravere Therapeutics, Inc. | 2.54B | 28.40 | -6.96 | 60.55% | -20.32% | -120.36% | 6.80 | |
| BEAMBeam Therapeutics Inc. | 3.25B | 32.05 | -7.00 | -83.18% | -7.44% | -42.92% | 0.22 | |
| SLNOSoleno Therapeutics, Inc. | 2.25B | 41.95 | -9.58 | -79.5% | -15.85% | 0.22 |
| Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|
| Sales/Revenue | 36K | 0 | 0 | 0 | 0 | 5.9M | 19.89M |
| Revenue Growth % | - | -1% | - | - | - | - | 2.37% |
| Cost of Goods Sold | 0 | 1.86M | 3.43M | 0 | 0 | 0 | 0 |
| COGS % of Revenue | - | - | - | - | - | - | - |
| Gross Profit | 36K | -1.86M | -3.43M | 0 | 0 | 5.9M | 19.89M |
| Gross Margin % | 1% | - | - | - | - | 1% | 1% |
| Gross Profit Growth % | - | -52.78% | -0.84% | 1% | - | - | 2.37% |
| Operating Expenses | 37.33M | 62.3M | 77.68M | 119.1M | 141.18M | 144.47M | 162.28M |
| OpEx % of Revenue | 1036.94% | - | - | - | - | 24.47% | 8.16% |
| Selling, General & Admin | 9.18M | 12.17M | 22.58M | 33.85M | 44.46M | 50.85M | 37.78M |
| SG&A % of Revenue | 254.94% | - | - | - | - | 8.61% | 1.9% |
| Research & Development | 28.15M | 50.13M | 58.53M | 85.25M | 96.72M | 93.62M | 61.3M |
| R&D % of Revenue | 782% | - | - | - | - | 15.86% | 3.08% |
| Other Operating Expenses | 0 | 0 | -3.43M | 0 | 0 | 0 | 63.2M |
| Operating Income | -37.29M | -62.3M | -81.11M | -119.1M | -141.18M | -138.56M | -142.39M |
| Operating Margin % | -1035.94% | - | - | - | - | -23.47% | -7.16% |
| Operating Income Growth % | - | -0.67% | -0.3% | -0.47% | -0.19% | 0.02% | -0.03% |
| EBITDA | -36.95M | -60.44M | -77.68M | -114.57M | -136.05M | -133.3M | -137.46M |
| EBITDA Margin % | -1026.31% | - | - | - | - | -22.58% | -6.91% |
| EBITDA Growth % | - | -0.64% | -0.29% | -0.47% | -0.19% | 0.02% | -0.03% |
| D&A (Non-Cash Add-back) | 347K | 1.86M | 3.43M | 4.53M | 5.13M | 5.26M | 4.93M |
| EBIT | -37.29M | -62.3M | -80.52M | -119.1M | -141.18M | -138.56M | -79.19M |
| Net Interest Income | 1.49M | 0 | 0 | 137K | 0 | 11.95M | 10.72M |
| Interest Income | 1.49M | 0 | 591K | 187K | 4.54M | 11.95M | 10.72M |
| Interest Expense | 0 | 0 | 591K | 50K | 4.54M | 0 | 0 |
| Other Income/Expense | 1.49M | 985K | 591K | -50K | 4.54M | 11.95M | 10.72M |
| Pretax Income | -35.8M | -61.32M | -80.52M | -119.15M | -136.64M | -126.61M | -131.67M |
| Pretax Margin % | -994.53% | - | - | - | - | -21.45% | -6.62% |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 1% | 0.98% | 1% | 1% | 1% | 1% | 1% |
| Net Income | -35.8M | -60.33M | -80.52M | -119.15M | -136.64M | -126.61M | -131.67M |
| Net Margin % | -994.53% | - | - | - | - | -21.45% | -6.62% |
| Net Income Growth % | - | -0.69% | -0.33% | -0.48% | -0.15% | 0.07% | -0.04% |
| Net Income (Continuing) | -35.8M | -61.32M | -80.52M | -119.15M | -136.64M | -126.61M | -131.67M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -18.20 | -13.10 | -29.54 | -21.17 | -23.51 | -19.63 | -19.76 |
| EPS Growth % | - | 0.28% | -1.25% | 0.28% | -0.11% | 0.17% | -0.01% |
| EPS (Basic) | -18.20 | -13.10 | -29.54 | -21.17 | -23.51 | -19.63 | -19.76 |
| Diluted Shares Outstanding | 1.97M | 4.62M | 2.73M | 5.63M | 5.81M | 6.45M | 6.66M |
| Basic Shares Outstanding | 1.97M | 4.62M | 2.73M | 5.63M | 5.81M | 6.45M | 6.66M |
| Dividend Payout Ratio | - | - | - | - | - | - | - |
| Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|
| Total Current Assets | 76.93M | 18.16M | 267.74M | 379.19M | 287.02M | 272.62M | 192.9M |
| Cash & Short-Term Investments | 74.87M | 15.08M | 262.33M | 375.14M | 279.09M | 264.36M | 185.22M |
| Cash Only | 7.3M | 15.08M | 62.89M | 375.14M | 93.17M | 66.45M | 76.3M |
| Short-Term Investments | 67.56M | 0 | 199.44M | 0 | 185.92M | 197.92M | 108.92M |
| Accounts Receivable | 1.29M | 448K | 0 | 0 | 660K | 4.15M | 1.56M |
| Days Sales Outstanding | 13.06K | - | - | - | - | 256.44 | 28.61 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - |
| Other Current Assets | 54K | 55K | 0 | 0 | 259K | 423K | 2.58M |
| Total Non-Current Assets | 6.59M | 23.98M | 26.42M | 97.58M | 89.25M | 102.14M | 38.29M |
| Property, Plant & Equipment | 4.49M | 21.84M | 23.78M | 91.03M | 81.42M | 95.65M | 35.6M |
| Fixed Asset Turnover | 0.01x | - | - | - | - | 0.06x | 0.56x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 2.11M | 2.05M | 0 | 0 | 0 | 5.79M | 0 |
| Other Non-Current Assets | 0 | 87K | 2.64M | 6.56M | 7.83M | 698K | 2.69M |
| Total Assets | 83.52M | 42.14M | 294.15M | 476.77M | 376.26M | 374.76M | 231.2M |
| Asset Turnover | 0.00x | - | - | - | - | 0.02x | 0.09x |
| Asset Growth % | - | -0.5% | 5.98% | 0.62% | -0.21% | -0% | -0.38% |
| Total Current Liabilities | 6.55M | 9.16M | 11.22M | 18.81M | 19.15M | 39.91M | 35.05M |
| Accounts Payable | 1.68M | 2.25M | 267K | 2.02M | 662K | 2.35M | 1.41M |
| Days Payables Outstanding | - | 440.78 | 28.4 | - | - | - | - |
| Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Current) | 4K | 1000K | 1000K | 0 | 0 | 1000K | 1000K |
| Other Current Liabilities | 0 | 2.28M | 702K | 8.26M | 8.4M | 1.24M | 8.63M |
| Current Ratio | 11.74x | 1.98x | 23.86x | 20.16x | 14.99x | 6.83x | 5.50x |
| Quick Ratio | 11.74x | 1.98x | 23.86x | 20.16x | 14.99x | 6.83x | 5.50x |
| Cash Conversion Cycle | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 118.56M | 131.57M | 14.92M | 76.22M | 74.62M | 131.72M | 109.94M |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 0 | 0 | 0 | 76.22M | 74.62M | 89.77M | 80.55M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | -41.94M | 0 |
| Other Non-Current Liabilities | 115.59M | 115.59M | 0 | 0 | 0 | 41.94M | 223K |
| Total Liabilities | 125.11M | 140.73M | 26.14M | 95.03M | 93.77M | 171.63M | 144.99M |
| Total Debt | 0 | 0 | 0 | 80.83M | 81.71M | 97.89M | 93.56M |
| Net Debt | -7.3M | -15.08M | -62.89M | -294.32M | -11.46M | 31.45M | 17.26M |
| Debt / Equity | - | - | - | 0.21x | 0.29x | 0.48x | 1.09x |
| Debt / EBITDA | - | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - | - |
| Interest Coverage | - | - | -137.25x | -2382.02x | -31.08x | - | - |
| Total Equity | -41.59M | -98.59M | 268.01M | 381.75M | 282.49M | 203.13M | 86.2M |
| Equity Growth % | - | -1.37% | 3.72% | 0.42% | -0.26% | -0.28% | -0.58% |
| Book Value per Share | -21.12 | -21.33 | 98.33 | 67.81 | 48.61 | 31.50 | 12.94 |
| Total Shareholders' Equity | -41.59M | -98.59M | 268.01M | 381.75M | 282.49M | 203.13M | 86.2M |
| Common Stock | 1K | 1K | 5K | 6K | 6K | 7K | 7K |
| Retained Earnings | -47.13M | -108.45M | -188.97M | -308.13M | -444.76M | -571.38M | -703.04M |
| Treasury Stock | -5.55M | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -9K | -115.59M | 9K | 0 | -83K | 274K | 159K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|
| Cash from Operations | -28.12M | -40.35M | -70.14M | -91.82M | -102.45M | -52.74M | -88.56M |
| Operating CF Margin % | -781.08% | - | - | - | - | -8.93% | -4.45% |
| Operating CF Growth % | - | -0.43% | -0.74% | -0.31% | -0.12% | 0.49% | -0.68% |
| Net Income | -35.8M | -61.32M | -80.52M | -119.15M | -136.64M | -126.61M | -131.67M |
| Depreciation & Amortization | 347K | 1.86M | 3.43M | 4.53M | 5.13M | 5.26M | 4.93M |
| Stock-Based Compensation | 3.49M | 0 | 8.41M | 17.86M | 0 | 24.34M | 14.61M |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | -834K | 3.88M | 249K | 766K | 28.02M | -9.27M | 54.99M |
| Working Capital Changes | 4.68M | 15.23M | -1.71M | 4.17M | 1.05M | 53.54M | -31.43M |
| Change in Receivables | -1.29M | 840K | 448K | 0 | -395K | -3.56M | -1.22M |
| Change in Inventory | 0 | 0 | -448K | 0 | 0 | 0 | 0 |
| Change in Payables | 223K | 761K | -1.44M | 1.76M | -1.39M | 1.09M | -386K |
| Cash from Investing | -69.76M | 47.98M | -205.2M | 193.05M | -192.51M | -9.7M | 94.53M |
| Capital Expenditures | -3.02M | -19.99M | -5.52M | -5.96M | -8.8M | -7.4M | -2.4M |
| CapEx % of Revenue | 83.92% | - | - | - | - | 1.25% | 0.12% |
| Acquisitions | - | - | - | - | - | - | - |
| Investments | - | - | - | - | - | - | - |
| Other Investing | -66.74M | 0 | -199.68M | 105K | 0 | 0 | 0 |
| Cash from Financing | 100.19M | 78K | 323.1M | 214.67M | 12.99M | 35.82M | 250K |
| Debt Issued (Net) | - | - | - | - | - | - | - |
| Equity Issued (Net) | - | - | - | - | - | - | - |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | - | - | - | - | - | - | - |
| Other Financing | 0 | -22K | 341K | 2.79M | -581K | -183K | -186K |
| Net Change in Cash | - | - | - | - | - | - | - |
| Free Cash Flow | -31.14M | -60.33M | -75.66M | -97.78M | -111.25M | -60.14M | -90.96M |
| FCF Margin % | -865% | - | - | - | - | -10.19% | -4.57% |
| FCF Growth % | - | -0.94% | -0.25% | -0.29% | -0.14% | 0.46% | -0.51% |
| FCF per Share | -15.81 | -13.06 | -27.76 | -17.37 | -19.14 | -9.33 | -13.65 |
| FCF Conversion (FCF/Net Income) | 0.79x | 0.67x | 0.87x | 0.77x | 0.75x | 0.42x | 0.67x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Metric | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | - | - | -95.06% | -36.68% | -41.14% | -52.14% | -91.02% |
| Return on Invested Capital (ROIC) | - | - | -133.04% | -61.07% | -59.08% | -41.11% | -63.18% |
| Gross Margin | 100% | - | - | - | - | 100% | 100% |
| Net Margin | -99452.78% | - | - | - | - | -2144.51% | -661.91% |
| Debt / Equity | - | - | - | 0.21x | 0.29x | 0.48x | 1.09x |
| Interest Coverage | - | - | -137.25x | -2382.02x | -31.08x | - | - |
| FCF Conversion | 0.79x | 0.67x | 0.87x | 0.77x | 0.75x | 0.42x | 0.67x |
| Revenue Growth | - | -100% | - | - | - | - | 236.92% |
| 2024 | |
|---|---|
| One Reportable | 19.89M |
| One Reportable Growth | - |
Generation Bio Co. (GBIO) reported $15.3M in revenue for fiscal year 2024. This represents a 42317% increase from $0.0M in 2018.
Generation Bio Co. (GBIO) grew revenue by 236.9% over the past year. This is strong growth.
Generation Bio Co. (GBIO) reported a net loss of $62.6M for fiscal year 2024.
Generation Bio Co. (GBIO) has a return on equity (ROE) of -91.0%. Negative ROE indicates the company is unprofitable.
Generation Bio Co. (GBIO) had negative free cash flow of $114.7M in fiscal year 2024, likely due to heavy capital investments.